Non-Invasive Cancer Diagnostics Market - Regional Analysis

On the basis of region, the global Non-Invasive Cancer Diagnostics Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds a dominant position in the non-invasive diagnostics market, owing to increasing incidence of cancer, increasing technological advancement, better reimbursement scenario, and governmental initiatives for screening of cancer in early stages. For instance, the American Cancer Society Guidelines for the early detection of cancer offers various screening plans at different ages. For example, the guidelines suggest that women between the age of 40 and 44 must screen for breast cancer annually. Moreover market players in the APAC region are involved in partnerships and agreements to enhance the market growth in cancer diagnostics. For instance, In April 2019, Halifax signed an exclusive distribution agreement with Genecast to make Immunoscore assay available in China.

Non-Invasive Cancer Diagnostics Market – Competitive Landscape

Some of the key players operating in the global non-invasive cancer diagnostics market include Roche Diagnostics, Hologic Inc., Qiagen, Gen-Probe Inc., Digene Corporation, Abbott Molecular, IVDiagnostics, Laboratory Corporation of America Holdings, OncoCyte Corporation, Arquer Diagnostics Ltd. and Affymetrix Inc.

Increasing product launches as a part of organic strategies to rule the market is also the key factor contributing to the non-invasive cancer diagnostics market growth. For instance, in March 2019, NeoGenomics Laboratories Inc. announced the launch of Ventana PD-L1 (SP142) Assay for tumor tissue testing in patients with a triple negative subtype of breast cancer. The test is approved by the US FDA for patients who might respond to TECENTRIQ, an immune checkpoint inhibitor in combination with chemotherapy.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1651

Non-invasive cancer diagnostics are procedures used for the identification of cancer without incision in the body. Detection and treatment of cancer at early stages are important for long-term survival. Non-invasive cancer detection method is found to be an increasing choice of interest, owing to its painless or minimal pain method of diagnostic coupled with more accurate results. Molecular based diagnostic methods are expected to increase during the forecast period due to launches of new biomarker based detection methods. Moreover, factors like increasing incidence of cancer, increasing cancer screening rate, government initiatives, and emerging technologies such as next generation sequencing are expected to drive the market during the forecast period.

According to Cancer Research UK, currently no diagnostic tests are 100% sensitive in general practice. This suggests the unmet demand for novel diagnostic assay with more efficiency. The efficiency of molecular diagnostics for screening of blood and tissue sample for cancer detection fuels the research and development of biomarker based molecular diagnostic method, which can detect abnormalities in their early developmental cycle. Moreover, according to Genome Biology article published in 2017, the current research in non-invasive cancer detection are targeting two class of studies - the development of biomarkers for a specific cancer type and the characterization of circulating tumor DNA (ctDNA) for general cancer detection, without trying to predict specific cancer types. Such studies will help manufacturers to develop better cancer detection kits for molecular based diagnostics.

Non-Invasive Cancer Diagnostics Market Drivers

Increasing incidence of cancer is expected to be a major factor driving growth of non-invasive cancer diagnostics market. Cancer is a major factor impacting the world economy. For instance, according to the World Health Organization (WHO) 2018 Factsheet, Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is occurred due to cancer.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/non-invasive-cancer-diagnostics-market-1651

Increasing rate of cancer detection will also boost the non-invasive cancer diagnostics market growth. According to the U.S. Breast Cancer Surveillance Consortium (BCSC) researchers, the rate of cancer detection increased to 34.7 per 1,000 individuals in 2013, as compared to 25.3 per 1,000 individuals in 2005. Furthermore, governmental and non-governmental organizations are engaged in raising awareness for breast and cervical cancer as well as conducts screening programme. The National Institute for Health and Care Excellence (NICE) is involved in improving diagnosis rate by revising draft guideline for early cancer detection. Moreover, increasing cancer studies for cancer drug development will boost the non-invasive cancer diagnostics market growth. In 2016, NCI's Center to Reduce Cancer Health Disparities launched the National ‘Screen to Save’ Colorectal Cancer Outreach and Screening Initiative. The initiative was aimed at increasing colorectal cancer screening rate.

Further, in 2016, Exosome Diagnostics, Inc. launched ExoDx Prostate (IntelliScore) test. The test uses genetic information from urine sample to evaluate patient risk for high grade prostate cancer.

In 2016, Laboratory Corporation of America Holdings, launched Epi proColon, the first FDA-approved DNA based blood test for colorectal cancer screening with FDA approval.

The inorganic strategies by market players are continuously boosting the non-invasive cancer diagnostics market. For instance, For instance, in November 2018, Belgian molecular diagnostics company, Biocartis Group entered into an agreement with AstraZeneca for development of lung cancer molecular diagnostic biomarker.

In 2017, Lonza, a biopharmaceutical development and manufacturing company, acquired HanaBioMaed Life Sciences OU, a company dedicated to research and development, manufacturing and distribution of products for the exosome genome market. Through this acquisition, company will invest to develop exosome-based early-stage cancer screening and molecular diagnostic tests. In same year, CORE Diagnostics partnered with CellMax Life to introduce CellMax’s genetic cancer risk test and ctDNA-based liquid biopsy throughout India.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1651

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737